A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML).
Hidenori AndoYuta MurakamiKiyoshi EshimaTatsuhiro IshidaPublished in: Cancer reports (Hoboken, N.J.) (2021)
The results of this study suggest that PEG-VTX could be an alternative therapeutic option for the safe and effective treatment of patients with AML.